Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric StrokeMay 15, 2017
Phase 3-ready program complements Biogen’s ongoing development efforts in stroke
Biogen will pay a $120 million upfront payment plus potential milestone and royalty payments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous glyburide). The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted CIRARA Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted CIRARA Fast Track designation.